Migraine is the second most disabling disorder across all age groups worldwide. Since
2018, two classes of drugs that inhibit the actions of calcitonin gene-related peptide (CGRP) …

Background: Calcitonin gene-related peptide (CGRP) targeted therapies are an important
breakthrough in migraine prevention. Randomized clinical trials, post-hoc analyses, and …

Background Criteria, including clinical features and effective outcomes, for access and
persistence of novel but costly treatments may vary between countries, thus affecting the …

Background Erenumab was approved in Europe for migraine prevention in patients with≥ 4
monthly migraine days (MMDs). In Spain, Novartis started a personalized managed access …

Background The CGRP antagonists offer a novel therapeutic approach in migraine. Their
utility in patients with severe forms of chronic migraine is a subject of particular interest. We …

Background Controlled and real-world evidence have demonstrated the efficacy of
calcitonin gene related peptide (CGRP) monoclonal antibodies (MABs) in migraine …

Background and objective We aimed to provide real-world data on the effectiveness of an
anti-calcitonin gene-related peptide monoclonal antibody administered for treating migraine …

Background Erenumab is a monoclonal antibody blocking the calcitonin gene–related
peptide receptor, which has been approved for the preventive treatment of chronic migraine …

Background Erenumab, the first-in-class fully human monoclonal antibody targeting the
calcitonin gene-related peptide receptor, was shown to be efficacious and safe for the …

Introduction Erenumab, a first-in-class monoclonal antibody targeting the calcitonin gene-
related peptide pathway, was approved by the US Food and Drug Administration in 2018 for …